Predictive value of C reactive protein (CRP) in patients with metastatic renal cell carcinoma (mRCC) treated with pembrolizumab (pembro) and axitinib (axi).

被引:0
|
作者
Qaisar, Aitzaz
Venugopal, Balaji
Ansel, Sonam
Jones, Robert J.
Slater, Sarah
Symeonides, Stefan N.
Malik, Jahangeer
Sundaramurthy, Aravindhan
Elliott, Tony
Devasar, Abeera
Stares, Mark
Randhawa, Manreet
机构
[1] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[2] Beatson Canc Ctr, Glasgow, Lanark, Scotland
[3] Univ Edinburgh, Edinburgh, Midlothian, Scotland
[4] Edinburgh Canc Ctr, Edinburgh, Midlothian, Scotland
[5] Western Gen Hosp, Edinburgh, Midlothian, Scotland
[6] NHS Lothian, Edinburgh, Midlothian, Scotland
关键词
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
716
引用
收藏
页数:1
相关论文
共 50 条
  • [1] Pembrolizumab plus axitinib (pembro plus axi) vs sunitinib in metastatic renal cell carcinoma (mRCC) outcomes of the KEYNOTE-426 study in patients from eastern Asia
    Kondoh, C. N.
    Bae, W. K.
    Tamada, S.
    Matsubara, N.
    Lee, H. J.
    Mizuno, R.
    Ani, S.
    Kimura, G.
    Tomita, Y.
    Chang, C-H.
    Chang, J. W-C.
    Lin, J.
    Perini, R.
    Molife, L. R.
    Powles, T. B.
    Rini, B.
    Chung, H-J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1319 - S1319
  • [2] Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
    Martin Pilskog
    Christian Beisland
    Lars A. Akslen
    Leif Bostad
    Åse Haug
    Daniel Heinrich
    Karin M. Hjelle
    Oddbjørn Straume
    BMC Urology, 17
  • [3] Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma
    Pilskog, Martin
    Beisland, Christian
    Akslen, Lars A.
    Bostad, Leif
    Haug, Ase
    Heinrich, Daniel
    Hjelle, Karin M.
    Straume, Oddbjorn
    BMC UROLOGY, 2017, 17
  • [4] Phase I/II study of axitinib (axi) and nivolumab (nivo) in patients with metastatic renal cell carcinoma (mRCC).
    Zibelman, Matthew R.
    Geynisman, Daniel M.
    Molina, Ana M.
    Malizzia, Lois
    Devarajan, Karthik
    Luong, Diana
    Sullivan, Elizabeth
    Carducci, Michael Anthony
    Plimack, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [5] Safety and efficacy of axitinib (axi) in combination with pembrolizumab (pembro) in patients (pts) with advanced renal cell cancer (aRCC).
    Atkins, Michael B.
    Plimack, Elizabeth R.
    Puzanov, Igor
    Fishman, Mayer N.
    McDermott, David F.
    Cho, Daniel C.
    Vaishampayan, Ulka N.
    George, Saby
    Olencki, Thomas
    Tarazi, Jamal Christo
    Rosbrook, Brad
    Fernandez, Kathrine C.
    Lechuga, Mariajose
    Choueiri, Toni K.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [6] Neoadjuvant pembrolizumab (PEMBRO) and axitinib (AXI) in renal cell carcinoma with associated inferior vena cava tumor thrombus (NEOPAX).
    Lakritz, Stephanie
    Candelario, Nellowe
    Nicklawsky, Andrew
    Kim, Simon P.
    Kessler, Elizabeth R.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : TPS488 - TPS488
  • [7] Pembrolizumab (pembro) and cabozantinib (cabo) in patients (pts) with metastatic renal cell carcinoma (mRCC): Phase I results.
    Keeler, Molika Emmeline
    Kessler, Elizabeth Riley
    Bernard, Brandon
    Weisdack, Sarah
    Breaker, Kathryn M.
    Wold, Mali
    Ertz, Donna
    Weitzenkamp, David
    Flaig, Thomas W.
    Lam, Elaine Tat
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [8] Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for locally advanced or metastatic renal cell carcinoma (mRCC): phase Ill KEYNOTE-426 study.
    Powles, Thomas
    Plimack, Elizabeth R.
    Stus, Viktor
    Gafanov, Rustem Airatovich
    Hawkins, Robert E.
    Nosov, Dmitry
    Pouliot, Frederic
    Alekseev, Boris Yakovlevich
    Soulieres, Denis
    Melichar, Bohuslav
    Vynnychenko, Ihor
    Kryzhanivska, Anna
    Bondarenko, Igor
    Azevedo, Sergio Jobim
    Borchiellini, Delphine
    Shou, Qiong
    Perini, Rodolfo F.
    Chen, Mei
    Atkins, Michael B.
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [9] Axitinib in combination with pembrolizumab (AXI plus PEMBRO) in patients (pts) with advanced renal cell carcinoma (aRCC): Analysis of immune-related biomarkers
    Atkins, Michael
    Martini, Jean-Francois
    Plimack, Elizabeth
    McDermott, David
    Puzanov, Igor
    Fishman, Mayer
    Cho, Daniel
    Vaishampayan, Ulka
    Rosbrook, Brad
    Fernandez, Kathrine
    Tarazi, Jamal
    George, Saby
    Choueiri, Toni
    CANCER RESEARCH, 2019, 79 (13)
  • [10] Takotsubo syndrome in a patient with metastatic renal cell carcinoma treated with pembrolizumab plus axitinib
    Airo, Giulia
    Maffezzoli, Michele
    Lazzarin, Alessandro
    Bianconcini, Michele
    Greco, Alessandro
    Buti, Sebastiano
    Leonetti, Alessandro
    IMMUNOTHERAPY, 2022, 14 (16) : 1297 - 1305